Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration

Pierluigi Iacono, Maurizio B. Parodi, Ugo Introini, Carlo La Spina, Monica Varano, Francesco Bandello

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 μm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 μm (P <0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalRetina
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • Age-related macular degeneration
  • Anti-VEGF
  • Intravitreal ranibizumab
  • Subfoveal choroidal neovascularization

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration'. Together they form a unique fingerprint.

Cite this